A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy

Matti Aapro(Clinique de Genolier), A. Macciocchi(Helsinn (Switzerland)), Florian Lordick(Leipzig University), S. Tjulandin(Russian Cancer Research Center NN Blokhin), George Manikhas(City Clinical Oncology Center), Brunello Morrica(Presidio Ospedaliero), Steven M. Grunberg(University of Bonn), T. Suarez(Universidad Marista de Mérida), L Bertoli(Southern Research Institute), F. Yunus, Guillermo Olivares(Centro Médico Nacional La Raza)
Annals of Oncology
June 10, 2006
10.1093/annonc/mdl137
Cited by 340

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k